LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase 2 study in metastatic NSCLC after prior PD-1/PD-L1 therapy and platinum chemotherapy, so the population is heavily pretreated and intrinsically hard to rescue. That lowers baseline odds of a clearly positive efficacy result. The primary endpoint is overall survival, which is clinically meaningful and difficult to manipulate, but it is also a hard endpoint to win on in a small mid-stage study because it is noisy, slow to mature, and influenced by subsequent therapies. A favorable aspect is that the superiority analysis compares TTFields plus pembrolizumab against docetaxel alone from the prior LUNAR/EF-24 study rather than a contemporaneous randomized control, which can make a positive readout somewhat easier if selection effects are favorable. Still, cross-study OS comparisons are methodologically fragile, and pembrolizumab in a previously PD-1/PD-L1-treated population is not an obviously high-probability backbone. The trial being just past estimated primary completion adds disclosure timing risk but not a decisive signal either way. Overall, I view success as plausible but below even odds.

LUNAR-4 (EF-50) was terminated by NovoCure in August 2025, as disclosed in an SEC filing and reported by multiple sources. The company stated it would rely on real-world evidence instead of completing this Phase 2 interventional trial. Since the trial was discontinued before reaching its primary completion date, there will be no formal positive readout of overall survival results. The predecessor LUNAR (EF-24) Phase 3 trial did meet its primary OS endpoint (HR 0.74, p=0.035), and TTFields received FDA approval for NSCLC in October 2024, which likely motivated the switch to real-world evidence. However, the question asks specifically whether LUNAR-4 results will be positive. A terminated trial cannot produce positive results in the conventional sense. The only residual probability (~5%) accounts for the unlikely scenario that partial data is published or the question resolution criteria somehow credit the real-world evidence substitution as a positive outcome.

This is a Phase 2 trial testing TTFields + pembrolizumab versus docetaxel in metastatic NSCLC patients who progressed on both PD-1/PD-L1 and platinum-based chemotherapy. The primary endpoint is overall survival superiority. NovoCure's TTFields have a mixed track record - the original LUNAR mesothelioma trial initially failed to meet its primary OS endpoint before showing some benefit in longer follow-up. This NSCLC population is heavily pretreated with limited options, which creates both medical need and biological challenges. Phase 2 trials with OS endpoints in refractory solid tumors face high variance and typically require strong effect sizes to achieve statistical significance. The market pricing at ~49.5% reflects substantial uncertainty. Given the prior mixed TTFields data, the challenging patient population, and Phase 2 sample size constraints, the intrinsic probability of a statistically significant positive result appears modestly below even odds.

This is a single-arm Phase 2 study in a heavily pre-treated metastatic NSCLC population, comparing overall survival to a historical control from a prior trial (LUNAR/EF-24). The historical control benchmark (docetaxel alone) is a weak comparator, making a statistically significant OS superiority claim challenging. The combination of Tumor Treating Fields with pembrolizumab is mechanistically novel but unproven in this setting after PD-1/PD-L1 inhibitor failure. While the sponsor has device experience, the operational risk is moderate given the single-arm design and reliance on external data. The primary completion date has passed, but results are not yet disclosed, adding typical binary outcome risk. The intrinsic odds appear below 50%.

This Phase 2 single-arm trial tests TTFields + pembrolizumab in metastatic NSCLC patients refractory to prior PD-1/PD-L1 inhibitors and platinum chemotherapy. Primary endpoint is OS superiority versus historical docetaxel control from LUNAR-2 (median OS ~11 months). Trial design risks include selection bias in single-arm historical comparison; refractory population has poor prognosis and diminished pembro efficacy (prior exposure reduces ORR to <10%, per KEYNOTE-010-like data). TTFields lacks proven NSCLC benefit—LUNAR-2 Phase 3 failed OS/PFS with docetaxel. No compelling prior data supports TTFields-pembro synergy; device compliance issues common (adherence ~70%). OS endpoint robust but requires mature data; small Phase 2 sample (implied n~60-100) limits power against historical median. Operational execution: active not recruiting, primary completion overdue 61 days, heightening disclosure risk if negative. Patient pop aggressive, heterogeneous. Overall, statistical superiority unlikely without large effect size.

LUNAR-4 leverages strong prior mechanistic data from the pivotal LUNAR/EF-24 trial, which demonstrated a significant overall survival benefit for TTFields combined with immune checkpoint inhibitors versus chemotherapy alone. By using pembrolizumab specifically in a PD-1/PD-L1 refractory metastatic NSCLC population, the trial targets a high-unmet-need niche where the synergy hypothesis is most plausible. The primary endpoint relies on a historical control comparison to the docetaxel arm of the predecessor study, a design that reduces placebo effect variance but introduces potential population drift bias. However, the device-drug combination has a well-characterized safety profile, minimizing operational derailment risks. With primary completion already passed by two months, the trial is in the analysis phase, eliminating enrollment execution risk. While historical control designs are inherently weaker than randomized comparisons, the robust magnitude of effect seen in the earlier study and the biological plausibility of the combination support a favorable outcome. Disclosure risk is minimal given the sponsor's established reporting history.

LUNAR-4 is a single-arm Phase 2 study testing TTFields plus pembrolizumab in heavily pretreated metastatic NSCLC patients (post-PD-1/PD-L1 and platinum). The primary endpoint is overall survival superiority versus historical docetaxel control from LUNAR/EF-24. This design carries substantial bias risk: cross-trial comparisons to historical controls are methodologically weak, patient populations may differ in prognostic factors, and post-PD-1 therapy outcomes are generally poor. TTFields showed modest benefit in the original LUNAR study (3-month OS improvement) but failed in other solid tumors. The 16-month target OS appears ambitious given the refractory population. Primary completion was January 2026 with data likely maturing now, suggesting near-term readout. No prior positive Phase 2 data in this specific setting exists. Disclosure risk is elevated given NovoCure's history of rapid trial result communication.

Novocure officially announced in late August 2025 that it has terminated the Phase 2 LUNAR-4 trial (NCT06558799). The company cited that the availability of real-world evidence would allow them to achieve the study's objectives without continuing this interventional clinical trial. Although management noted the discontinuation was not related to safety concerns, a terminated trial cannot successfully meet its primary endpoint of overall survival (OS) compared to a historical control (the LUNAR/EF-24 study). Because LUNAR-4 will not be completed or reach its planned readout, it is practically impossible for the trial to yield a formally positive result. Instead of full data, the trial is closed. Consequently, the likelihood of a YES resolution is zero, driven entirely by the sponsor's operational execution decision to wind down the study prematurely rather than any clinical data readout.

The LUNAR-4 trial is investigating the effectiveness of Tumor Treating Fields (TTFields) therapy concomitant with pembrolizumab in metastatic NSCLC patients. The trial's design, testing a combination of TTFields with pembrolizumab, a known effective treatment, suggests potential for positive outcomes. The primary endpoint of Overall Survival is a strong, clinically relevant measure. Given the mechanism of TTFields and its previous use in glioblastoma, there's a rationale for efficacy in NSCLC. However, the Phase 2 status and the relatively small sample size introduce uncertainty. The trial's active status and the sponsor's experience with TTFields support a positive probability but not a certainty.